Paper38366267
Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D and 8 others. Eur J Pediatr, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study. Papers, record 38366267. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38366267
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pyridazines | Major topic |
| Phenylpropionates | Major topic |
| Pulmonary Arterial Hypertension | Major topic |
| Humans | |
| Male | |
| Child | |
| Female | |
| Adolescent | |
| Treatment Outcome | |
| Antihypertensive Agents | |
| Dose-Response Relationship, Drug | |
| Walk Test | |
| Hypertension, Pulmonary |
Source PubMed
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33765691 | Endothelin receptor antagonists for pulmonary arterial hypertension. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/33765691 | PubMed |
| 2 | 36017548 | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. | Eur Heart J | 2022 | https://conductscience.org/library/papers/36017548 | PubMed |
| 3 | 21947294 | Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. | Circulation | 2011 | https://conductscience.org/library/papers/21947294 | PubMed |
| 4 | 8497283 | Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. | N Engl J Med | 1993 | https://conductscience.org/library/papers/8497283 | PubMed |
| 5 | 21419223 | The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. | Pharmacol Res | 2011 | https://conductscience.org/library/papers/21419223 | PubMed |
| 6 | 37332660 | A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. | J Pediatr X | 2020 | https://conductscience.org/library/papers/37332660 | PubMed |
| 7 | 18506008 | Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. | Circulation | 2008 | https://conductscience.org/library/papers/18506008 | PubMed |
| 8 | 22511577 | Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. | Pediatr Pulmonol | 2013 | https://conductscience.org/library/papers/22511577 | PubMed |
| 9 | 36579617 | Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data. | J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/36579617 | PubMed |
| 10 | 26386921 | FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. | Int J Cardiol | 2016 | https://conductscience.org/library/papers/26386921 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42390808 | SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42390808 | PubMed |
| 41923739 | Synergistic Cardiopulmonary Protection of Endothelin Receptor Antagonists Combined With Soluble Guanylate Cyclase Agonists in High-Risk Coronary Syndrome With Pulmonary Hypertension. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/41923739 | PubMed |
| 39734932 | Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension. | Pulm Circ | 2024 | https://conductscience.org/library/papers/39734932 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38366267
GET https://conductscience.org/api/papers/v1/38366267/authors